TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, announced the retirement of Chief Financial Officer Tom Fitzgerald, who has served in the role since July 2018. Fitzgerald will resign as CFO and a director effective immediately while continuing to provide transition services. The company named John Tattory interim CFO, effective immediately.
Tattory brings more than 25 years of financial and operational management and leadership experience across pharmaceutical, medical device and biotechnology companies, including roles at Ernst & Young LLP, Bristol-Myers Squibb, Tyco International, Cerapedics and Windtree Therapeutics. He currently serves as a managing director at Stout Risius Ross, where he provides consulting CFO services primarily to privately held life science companies.
The leadership change comes at a critical time for TransCode Therapeutics, which is focused on developing innovative treatments for high-risk and advanced cancers. The company’s lead therapeutic candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells.
For investors and industry observers, the appointment of an interim CFO with extensive life science financial experience may signal stability and continuity as the company advances its clinical programs. Tattory’s background in both large pharmaceutical firms and consulting for private life science companies could be particularly valuable as TransCode navigates the complex financial landscape of clinical-stage drug development. The transition period, with Fitzgerald providing transition services, may help ensure a smooth handover of financial responsibilities.
The news is relevant to stakeholders in the biotechnology and oncology sectors, as TransCode’s progress in developing RNA-based cancer therapies could have broader implications for treatment options. The company’s focus on microRNA-10b as a biomarker for metastasis represents a novel approach that, if successful, could address significant unmet needs in metastatic cancer treatment.
To view the full press release, visit https://nnw.fm/8G3ik. The latest news and updates relating to RNAZ are available in the company’s newsroom at https://nnw.fm/RNAZ.
